Your Health, We Care
Release date: 2024-08-26 17:14:57 Recommended: 115
Alpelisib is the first PI3K inhibitor specifically for PIK3CA-mutated breast cancer and can be used in combination with fulvestrant to significantly prolong progression-free survival. By inhibiting the PI3K pathway, Alpelisib can effectively reduce the proliferation and spread of tumor cells, which has become a powerful tool for precision therapy.
Alpelisib has shown significant efficacy in breast cancer patients with PIK3CA mutations.
The final overall survival (OS) analysis showed no significant difference in OS between the combination of Alpelisib and fulvestrant and placebo. For patients with no PIK3CA mutation detected in the tumor, the treatment effect was not significant.
Alpelisib combined with fulvestrant has shown significant efficacy in breast cancer patients with PIK3CA mutations, and the applicable population of Alpelisib will be discussed below to further clarify the scope of drug therapy.
Alpelisib is primarily used in patients with specific types of breast cancer, particularly those with PIK3CA mutations.
Alpelisib in combination with fulvestrant is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated advanced or metastatic breast cancer in postmenopausal women and men. These patients had their cancers confirmed with an FDA-approved assay after their cancer progressed on endocrine therapy.
The combination of apelis and fulvestrant is indicated for patients with certain types of advanced or metastatic breast cancer. Understanding possible adverse effects is essential to manage side effects during treatment.
Apelis may trigger some side effects, and understanding these can help you better manage and cope.
The use of this medication may cause significant weight loss, which may affect overall health and nutritional status. The cause of weight change should be assessed and appropriate interventions should be initiated.
Medications can cause calcium levels in the blood to drop, triggering decreased bone density or muscle cramps. Calcium supplementation or modification of treatment regimens may help alleviate these problems.
Weight loss and reduced calcium levels are possible side effects of using the drug. Timely monitoring of these adverse effects and taking appropriate measures is essential to maintain the health of patients.
[Warm tips] During the use of Alpelisib, please have regular physical examinations and laboratory tests to monitor for potential adverse reactions. If you experience abnormal symptoms or discomfort, contact your medical provider promptly to adjust your treatment plan.
